Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for military-related posttraumatic stress disorder.  For more information, please visit www.thehonorstudy.com or www.clinicaltrials.gov (NCT03062540).

Financial Info
: Financials

Financials

v3.7.0.1
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($)
$ in Thousands
Mar. 31, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 19,943 $ 18,941
Marketable securities-available for sale, at fair value 2,480 7,180
Prepaid expenses and other 1,009 1,019
Total current assets 23,432 27,140
Property and equipment, net 132 150
Restricted cash 89 89
Intangible asset 120 120
Security deposits 11 11
Total assets 23,784 27,510
Current liabilities:    
Accounts payable 841 872
Accrued expenses 939 1,244
Total current liabilities 1,780 2,116
Deferred rent payable 29 33
Total liabilities 1,809 2,149
Commitments (See Note 8)
Stockholders' equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized, none issued or outstanding
Common stock, $0.001 par value; 15,000,000 shares authorized; 4,160,814 and 3,918,147 shares issued and outstanding as of March 31, 2017andDecember31,2016, respectively, and 2,496 shares to be issued as of December 31, 2016 4 4
Additional paid in capital 168,283 166,604
Accumulated deficit (146,304) (141,240)
Accumulated other comprehensive loss (8) (7)
Total stockholders' equity 21,975 25,361
Total liabilities and stockholders' equity $ 23,784 $ 27,510
v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
COSTS AND EXPENSES:    
Research and development $ 2,994 $ 10,671
General and administrative 2,097 3,343
Total costs and expenses 5,091 14,014
Operating loss (5,091) (14,014)
Interest income, net 27 38
NET LOSS $ (5,064) $ (13,976)
Net loss per common share, basic and diluted (in dollars per share) $ (1.27) $ (7.41)
Weighted average common shares outstanding, basic and diluted (in shares) 3,985,529 1,886,043
v3.7.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (5,064) $ (13,976)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 24 57
Stock-based compensation 567 896
Changes in operating assets and liabilities:    
Prepaid expenses 10 178
Accounts payable (31) (986)
Accrued expenses (307) (1,645)
Deferred rent payable 7 (9)
Net cash used in operating activities (4,794) (15,485)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of furniture and fixtures (65)
Maturities of marketable securities 4,694 4,783
Net cash provided by investing activities 4,694 4,718
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds, net of expenses of $34 from sale of common stock 1,102
Net cash provided by financing activities 1,102
Effect of currency rate change on cash 19
Net increase (decrease) in cash 1,002 (10,748)
Cash, beginning of the period 18,941 19,175
Cash, end of period 19,943 8,427
Non-cash financing activities:    
Issuance of common stock under employee benefit plan $ 10 $ 113